PRESS RELEASE published on 02/07/2024 at 07:30, 2 years 4 months ago EQS-Adhoc: CTS EVENTIM: Dynamic growth across all business segments produces record results for 2023 CTS EVENTIM AG & Co. KGaA achieved a record revenue of EUR 2.359 billion in 2023, representing a 22.5% increase year-on-year. Both Ticketing and Live Entertainment segments drove the growth, with a 32.5% increase in Ticketing segment revenue and a 18.9% increase in Live Entertainment segment revenue Record Revenue CTS EVENTIM Annual Results Dynamic Growth Business Segments
PRESS RELEASE published on 01/31/2024 at 11:30, 2 years 4 months ago CTS EVENTIM - The European Handball Federation and CTS EVENTIM agree long-term extension to strategic partnership The European Handball Federation and CTS EVENTIM have extended their strategic ticketing partnership for the long term, aiming to enhance customer experience and international fan base for EHF EURO tournaments Strategic Partnership European Handball Federation CTS EVENTIM EHF EURO Tournaments International Customer Database
PRESS RELEASE published on 01/23/2024 at 10:57, 2 years 5 months ago CTS EVENTIM – New leadership at Finnish ticketing subsidiary Lippupiste This press release announces the new CEO of Lippupiste, Finland's leading ticketing provider, as Juhana Stenbäck. Long-standing CEO, Ari Palhamo, will be stepping down and taking up a position on the company's Board of Directors. Stenbäck, who has been part of the management since 2020, will provide continuity and aims to continue driving the company forward with his expertise and experience in the ticketing business. Lippupiste Juhana Stenbäck Ari Palhamo Ticketing Provider Finnish Market
PRESS RELEASE published on 10/05/2023 at 15:28, 2 years 8 months ago EQS-Adhoc: CTS EVENTIM delivers a strong performance in the third quarter and raises its forecast for 2023 as a whole
PRESS RELEASE published on 10/05/2023 at 09:01, 2 years 8 months ago CTS EVENIM: Arne Fritz becomes new Vice President Venues & Real Estate
PRESS RELEASE published on 09/18/2023 at 12:20, 2 years 9 months ago CTS EVENTIM and Austrian Ski Association agree long-term partnership
PRESS RELEASE published on 09/14/2023 at 12:03, 2 years 9 months ago CTS EVENTIM has launched the second construction phase of its new ARENA FOR MILAN in the Santa Giulia area – the most modern sports and live entertainment arena in Italy.
PRESS RELEASE published on 08/24/2023 at 07:30, 2 years 10 months ago CTS Eventim AG & Co. KGaA: Dynamic growth across all business segments
PRESS RELEASE published on 08/02/2023 at 17:57, 2 years 10 months ago EQS-Adhoc: Exercise of Call Option to acquire 17% of the share capital of France Billet
PRESS RELEASE published on 07/05/2023 at 17:41, 2 years 11 months ago EQS-Adhoc: CTS Eventim AG & Co. KGaA: Consent to the proposed settlement in the car toll dispute arbitration proceedings
Published on 06/26/2026 at 14:05, 1 hour 24 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 29 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 29 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 44 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:17, 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 06/26/2026 at 15:17, 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Personal Finance plc
Published on 06/26/2026 at 15:16, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Gamma Communications plc
Published on 06/26/2026 at 07:00, 8 hours 29 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 29 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel